医学
生活质量(医疗保健)
横断面研究
甲状腺癌
置信区间
内科学
甲状腺
甲状腺切除术
病理
护理部
作者
Min Ji Jeon,Yu‐Mi Lee,Tae‐Yon Sung,Minkyu Han,Yong‐Wook Shin,Won Gu Kim,Tae Yong Kim,Ki‐Wook Chung,Young Kee Shong,Won Bae Kim
出处
期刊:Thyroid
[Mary Ann Liebert, Inc.]
日期:2019-04-30
卷期号:29 (7): 956-962
被引量:96
标识
DOI:10.1089/thy.2018.0711
摘要
Background: Active surveillance (AS) is recommended as an alternative to immediate surgery in patients with papillary thyroid microcarcinoma (PTMC), but the impact of AS on quality of life has not been reported. The aim of this study was to compare quality-of-life parameters in patients with PTMC under AS versus those who underwent lobectomy (LB). Methods: In this cross-sectional study, patients with PTMC were prospectively enrolled between June 2016 and October 2017. All patients completed three questionnaires: the 12-item short-form health survey, thyroid cancer-specific quality of life, and fear of progression. The results were compared after adjusting for age, sex, and serum thyrotropin levels. Results: The AS group comprised 43 patients, and the LB group comprised 148 patients. According to the 12-item short-form health survey questionnaire, the score for role limitations due to emotional problems showed a significant negative association between the groups (coefficient [coef]: -7.71 [confidence interval (CI) -15.26 to -0.16], p = 0.045). The thyroid cancer-specific quality of life questionnaire also showed statistically significant differences between the groups with respect to three scores: neuromuscular problems (coef: 4.99 [CI 0.63-10.62], p = 0.020), throat/mouth problems (coef: 5.28 [CI 0.18-10.38], p = 0.043), and scar problems (coef: 9.34 [CI 4.38-14.29], p < 0.001), suggesting a higher level of complaint in the LB group than in the AS group. No significant differences in fear of progression scores were seen between the two groups. Conclusions: Patients with PTMC underwent LB experienced more health-related problems than those managed by AS. These findings support the role of AS as a reasonable management option for patients with PTMC.
科研通智能强力驱动
Strongly Powered by AbleSci AI